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 Objective:  We aimed to assess documentation completeness of the operative record for mesh 
implanted at the time of midurethral sling surgery and to identify modifiable predictors of 
documentation completeness.  
Methods:  A retrospective cross-sectional study of women with stress incontinence that 
underwent midurethral sling placement between 1/2009 and 12/2011 was conducted. Data from 
the dictated operative note and nursing operative record were extracted to determine if the 
specific mesh implanted during surgery was documented. The primary outcome was the rate of 
documentation of mesh implanted in the physician’s dictated operative note and in the nursing 
record. Logistic regression was used to determine if any characteristics were associated with the 
rate of documentation. 
 Results: There were 816 surgeries involving the implantation of a midurethral sling during the 
study period. A Urogynecologist dictated 71% of the operative notes.  The rate of documentation 
completeness for mesh implanted in the physician’s note was 10%. The rate of documentation 
completeness for mesh implanted in the nursing operative record was 92%. Documentation of 
mesh implanted in the physician’s note was not significantly associated with level of training, 
specialty, or year of surgery.  
Conclusion: Documentation completeness for specific mesh implant in the physician’s note is 
low, independent of specialty and level of training.   Nursing documentation practices are more 
rigorous. Post-market surveillance, currently mandated by the FDA, may not be feasible if only 
the physician’s note is available or if nursing practices are inconsistent. Development of 
documentation guidelines for physicians would improve feasibility of surveillance.  
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Introduction: Stress urinary incontinence (SUI) is a common problem affecting 15-50% of 
community-dwelling women (1,2). While initial treatment is often nonsurgical, surgery is offered 
to women with persistent symptoms. An estimated 4 to 10% of women in the United States 
undergo surgery to restore urinary continence (3). Surgical treatment frequently involves the 
placement of a synthetic midurethral sling. According to the Food and Drug Administration 
(FDA), in 2010 approximately 260,000 women underwent surgery to treat SUI and over 80% 
involved transvaginal mesh (4). Multiple products exist for SUI, all of which received FDA 
approval as Class II devices under the 510(K) Premarket Notification Program. In 2011, the FDA 
issued a Safety Communication to inform clinicians and patients that complications related to 
urogynecologic mesh are not rare (5). In 2012, the FDA mandated continued analysis of the 
literature, surveillance of adverse events, and further research on safety and effectiveness of 
surgical mesh including post-market (“522”) studies by manufacturers. Although they focused on 
vaginal mesh for prolapse, continued surveillance of midurethral slings was also specified.  The 
specific mesh implant used must be completely and accurately documented, either within the 
physician’s note or the nursing record, to effectively conduct this mandated reporting and 
research.   
We aimed to assess documentation completeness of the operative record for the specific 
mesh implanted at the time of midurethral sling surgery and to identify modifiable predictors of 
documentation completeness. This will help determine if post-market surveillance utilizing 
institution based medical records is feasible given current practice and documentation patterns.  
Materials and Methods: A retrospective cross-sectional study of women presenting with stress 
incontinence that underwent midurethral sling placement at one of six Indiana University Health 
hospitals was conducted between January 1st 2009 and December 31st 2011. This study was 
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approved by the Institutional Review Board at Indiana University. Eligible subjects were 
identified by querying the Indiana University Health electronic medical record for surgical 
procedure name.  Although the Indiana University Health system includes 17 adult hospitals, the 
surgical records of just 6 of these 17 hospitals were available for electronic querying. As such, 
only surgeries conducted at these 6 facilities were included in our analysis.   All women with 
SUI who underwent midurethral sling placement during our study period were eligible for 
inclusion. Any subjects in whom the surgeon’s operative note or the nursing operative record 
was not available for electronic review, or in whom a midurethral sling was not actually 
implanted, were excluded. Each eligible subject’s operative note and nursing operative record 
was then individually reviewed. Data was extracted to determine if the specific urogynecologic 
mesh implanted at the time of surgery had been appropriately documented in each of these 
records. A strict definition was applied for documentation completeness requiring identification 
of both the manufacturer name as well as the product name of the specific mesh implanted. For 
instance, reporting “Boston Scientific Advantage” and “AMS Monarc” would qualify as 
complete documentation for the specific mesh implanted, while “TVT”, “TOT”, and “tension 
free vaginal tape” would not.   
The primary outcome was to assess the rate of documentation completeness for specific 
mesh implanted in the physician’s dictated operative note and in the nursing operative record. In 
the records in which a specific mesh implant was dually identified in both the physician’s 
operative note and in the nursing operative record, we were able to calculate concordance and 
discordance rates. Secondary variables collected included rates of documentation of product code 
(a unique identifier assigned by the manufacturer to distinguish a specific product) and lot 
number (which pinpoints where and when the product was produced and provides traceability), 
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indication for surgery, use of concomitant cystoscopy, and actual product implanted.  Clinical 
characteristics such as year of surgery, institution, surgical specialty and level of training of 
dictating surgeon were collected as possible predictors of documentation completeness.  
Statistical analysis was conducted using SPSS 20.0 software. Descriptive statistics were 
performed. Categorical variables are reported as frequencies and percentages while continuous 
variables are reported as means with standard deviations.  Logistic regression was used to 
determine if the year of surgery, institution, surgical specialty, or level of training of the dictating 
surgeon were independent predictors of documentation completeness for the specific implant in 
both the physician and nursing records using separate models. Generalized estimating equation 
(GEE) methodology assuming compound symmetry correlation structure was used to account for 
the correlation of subjects from the same dictating physician. The Chi-square likelihood ratio test 
was used. Odds ratios and 95% confidence intervals were calculated. P≤0.05 was considered 
statistically significant.  
Results: There were 816 surgeries involving the implantation of a midurethral sling during the 
study period. 55% (n=448) of the surgeries were performed at a single institution, 27% (n=219) 
were performed at a second institution, and the remaining 18% (149) were performed at the 
remaining 4 institutions. 71% (n=584) of the operative notes were dictated by a Urogynecologist, 
17% (n=136) by an Obstetrician Gynecologist, and 12% (n=96) by a Urologist. 38% (n=308) of 
the operative notes were dictated by an attending physician, 60% (n=492) by a fellow, and 2% 
(n=16) by a resident.  The average age of our subjects was 56 years (SD 12.8). A documented 
indication for midurethral sling implantation such as “stress incontinence”, “urodynamic stress 
incontinence” or “stress predominant mixed incontinence” was noted in 95% of cases. 
Concomitant cystoscopy was documented in 96% of cases.   
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The rate of documentation completeness for the specific mesh implanted in the 
physician’s dictated operative note was 10% (n=84). Only 4.5% had both a manufacturer and 
product name documented under the “Procedures” heading of the of the physician’s operative 
note and only 1.7% had both a manufacturer and product name documented in the body of the 
physician’s operative note. Thus careful review of the entire physician’s dictated operative note 
was required to obtain even the low rate of documentation completeness (10%) described above.  
The rate of documentation completeness for the specific mesh implanted in the nursing operative 
record was 92% (n=748).  A product number and lot number were documented in 98% of cases 
in the nursing operative record.   There was 11% (n=8) discordance or disagreement in the 68 
records in which a specific mesh implant was identified in both the physician’s operative note 
and the nursing operative record. In 6 of these 8 cases, the discordance resulted from inaccurate 
documentation of product name in the physician’s dictated note. The most frequent product 
implanted was the Gynecare TVT™ Retropubic sling, 57% (n=420), followed by the AMS 
Monarc™ trans-obturator sling, 23% (n=166).     
 The dictating physician’s level of training (Attending vs. Fellow/Resident, P=0.145), 
surgical specialty (Urogynecology vs. Obstetrics and Gynecology vs. Urology, P=0.720), and 
year of surgery (2009 vs. 2011, P=0.419) were not predictors of documentation completeness for 
the specific mesh implanted in the physician’s dictated operative note.    
However, year of surgery did predict the rate of documentation completeness for the 
specific mesh implant in the nursing operative record (P<0.001) with an 86% documentation rate 
in 2009 and a 96% documentation rate in 2011. Institution also predicted the rate of 
documentation completeness for the specific mesh implant in the nursing operative record 
(P=0.005), with documentation rates ranging from 73% to 95%. In addition, year of surgery 
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(P=0.009, OR 2.52, 95% CI 1.2-5.03) and institution (P=0.011) remained independent predictors 
of the rate of documentation completeness for the specific mesh implant in the nursing operative 
record when both were included as explanatory variables in a single logistic regression model.   
Discussion:  Documentation completeness for the specific mesh implanted at the time of surgery 
in the physician’s operative note is low upon review of more than 800 midurethral sling surgeries 
performed at 6 institutions by over 30 surgeons. This was independent of surgical specialty and 
level of training of the dictating physician.  Nursing documentation practices in our health 
system are more rigorous with a higher rate of documentation completeness in the nursing 
operative record. This was institution dependent, with a wide range of documentation rates. In 
addition, rates of documentation improved over the course of our study period. The high rate of 
documentation completeness in the nursing record may be related to specific guidelines and 
training that nurses within our system receive regarding surgical implants. Nurses are required to 
document the name, product and lot number of any surgical implant. In addition, they use a 
templated electronic medical record containing prompts and fields for documentation of 
permanent implants. While this may differ between systems, physicians have no specific 
guidelines for documentation of surgical implants. They also often dictate operative reports 
rather than using templated electronic records. Finally, it is likely that nursing documentation 
occurs during the surgery, in the operating room, with ready availability of implant packaging, 
while surgeon documentation often occurs outside of the operating room.    
These findings raise questions about the feasibility of FDA mandated post-market 
surveillance of urogynecologic mesh devices within the current system. In their Guidance 
document (6), the FDA suggests that surveillance should be conducted and references the use of 
secondary data sets, registries and tracking systems which allow for analysis of outcomes. The 
  Nadine C. Kassis 
 
8 
Documentation of specific mesh implant 
document cautions “In these instances, it is important to ensure that variables of interest are 
included in the data set.” In addition, the Committee Opinion released by the American College 
of Obstetricians and Gynecologists and the American Urogynecologic Society (AUGS) on the 
Vaginal Placement of Synthetic Mesh for Pelvic Organ Prolapse emphasizes the importance of 
continued surveillance with support of “continued audit and review of outcomes, as well as the 
development of a registry for surveillance…” (7). Many patients present to tertiary centers with 
mesh complications, and the ability to report to an adverse event registry becomes significantly 
hampered by lack of specific implant data.  
Our findings are similar to those seen by Dr. Ballard and colleagues (8).  Using a health 
information exchange containing data from 20 hospital systems, they were able to review over 
2000 cases in which a urogynecologic mesh device was placed transvaginally.  They identified 
the specific device used for the treatment of SUI in only 28% of cases, consistent with the low 
documentation rate in our study. On the other hand, they were able to identify the specific mesh 
device used for the treatment of prolapse in 86% of cases, a much higher rate of documentation 
completeness. Nursing documentation practices were not assessed. In their discussion, the 
authors recommend the inclusion of a unique device code in the medical record to allow for more 
automated and accurate surveillance. 
Recent cardiac literature has demonstrated success with automated surveillance using 
device registry data.  In one study evaluating 70,000 procedures, automated surveillance of the 
device registry was able to detect low-frequency safety signals arising from complications 
related to new cardiac devices (9). The Pelvic Floor Disorders Outcome Registry, currently 
under development by AUGS, will be crucial in providing much needed information about the 
effectiveness and safety associated with implantation of urogynecologic mesh, given this 
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previous experience.  While device registries rely on voluntary reporting, entry into the registry 
at time of the index surgery will allow for accurate data collection and will facilitate automated 
surveillance for adverse events and efficacy.   
All of the surgeries reviewed in our analysis were performed within a single system. This 
may limit the generalizability of our findings. However, 6 institutions and 30 surgeons were 
included in this analysis. In addition, we chose to be rigorous with the definition of 
“documentation completeness” requiring both manufacturer and product name. We did so 
because there are more than 20 slings currently being marketed. Additionally, we have noted a 
trend for describing any retropubic sling as a “TVT” even though TVT is a trademarked product 
name. Requiring only a product name would have resulted in higher documentation 
completeness rates but would have misrepresented accuracy.    
Adverse event reporting, utilizing data from electronic medical records, may not be 
presently feasible if only the physician’s note is available or if nursing practices are not 
consistent across systems. Improved documentation is required so that accurate information 
about outcomes following mesh implantation can be used to drive healthcare decision making. 
Development of documentation guidelines for physicians, requiring identification of implants by 
both manufacturer and product name, and by product and lot number, would likely improve 
documentation rates and the feasibility of post-market surveillance. Continued support for the 
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